Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Interventional
Phase 2
West China Hospital of Sichuan University
Sponsor: Zelgen Biopharmaceuticals
Last Updated: March 25, 2025 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Treatment Category
Other Drugs, Monoclonal Antibodies, Checkpoint Inhibitors